[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362461-105":59,"doc-detail-362461-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","brief-report-immune-checkpoint-inhibitors-use-in-lung-cancer-a-real-world-outcome-study-in-a-middle-income-country","Brief report: immune checkpoint inhibitors use in lung cancer - a real-world outcome study in a middle-income country","","Retrospective, multicenter cohort data from Morocco evaluated real-world use of immune checkpoint inhibitors (ICIs) for lung cancer across public and private oncology centers between January 2019 and January 2022. The study assessed survival outcomes, response rates, and time to treatment discontinuation, reporting descriptive and statistical comparisons. Among 158 treated advanced lung cancer cases, treatment discontinuation occurred after a median of 13.53 months, with 12-month overall survival of 71.1% and median overall survival of 17 months. Adverse events appeared in 40%, including grade 3–4 toxicities in 9.3%.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/brief-report-immune-checkpoint-inhibitors-use-in-lung-cancer-a-real-world-outcome-study-in-a-middle-income-country/362461/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/brief-report-immune-checkpoint-inhibitors-use-in-lung-cancer-a-real-world-outcome-study-in-a-middle-income-country/362461.png","ImageObject",300,407,{"name":92,"@type":93},"Connor ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of the study on immune checkpoint inhibitors in lung cancer?","Question",{"text":112,"@type":113},"To evaluate how immune checkpoint inhibitors were used for lung cancer and to assess the real-world data from Morocco.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What study design and patient time window were used?",{"text":117,"@type":113},"A retrospective, multicenter cohort study included Moroccan patients diagnosed between January 2019 and January 2022 and treated with ICIs.",{"name":119,"@type":110,"acceptedAnswer":120},"What survival outcomes and safety signals were reported?",{"text":121,"@type":113},"The median time to discontinuation was 13.53 months, with 12-month overall survival of 71.1% and median overall survival of 17 months; adverse events occurred in 40%, with grade 3–4 toxicities in 9.3%.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362461,1791037301,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Benbrahim etal. BMC Cancer (2026) 26:267 BMC Cancer  \n[https://doi.org/10.1186/s12885-025-15008-9](https://doi.org/10.1186/s12885-025-15008-9)  \nRESEARCH Open Access  \nBrief report: immune checkpoint inhibitors  \nuse in lung cancer: a real-world outcome study in a middle-income country  \nZineb Benbrahim1, Oumaima Siyouri1*, Mohamed Fetohi 1, Nadia Benchakroun2, Nabil Ismaili3, Nssiba Bahra4, NabilTachfouti4, Brahim El Ghissassi5, Fatima Zahra El M’Rabet6, Rhizlane Belbaraka7, Ali Tahri8, Abdelkader Acharqi9 and Nawfel Mellas 1  \nAbstract  \nIntroduction Lung cancer is the leading cause of cancer death in the world and its treatment represents a major challenge. Treatment with immune checkpoint inhibitors (ICIs) uses cutting-edge technologies and mobilizes a large number of clinical research players. However, the cost may be a barrier to access to these treatments in developing countries. The objective of this study was to evaluate the use of ICIs in lung cancer and assess real-world data of this treatment in Morocco.  \nMethods This is a retrospective, multicenter cohort study conducted in a Moroccan population diagnosed with lung cancer between January 2019 and January 2022 and treated with ICIs. Patients were recruited from public and private oncology centers ofthe whole kingdom. Agreement of the ethics committee has been obtained. Survival data, response rates and time till discontinuation of treatment were evaluated using the chi-square test and bivariate analyzes.  \nResults We included 158 cases representing 5 % of the total number of patients with advanced lung cancer who were eligible for treatment with ICIs. The mean age of patients was 62.48 years and the sex ratio (male/female) was of 4.41. Seventy percent of patient had non-squamous cell carcinoma. EGFR status was mutated in 3. 9% of the cases. In 34. 2% of the cases, the PD-L1 expression status was not known. Forty-seven percent of patients were treated with ICIs monotherapy. Fifty-eight percent of ICIs prescription was in the frontline treatment of lung cancer. The median time to discontinuation of treatment was 13.53 months. The 12-month overall survival rate was 71. 1%(95% CI: 62 .5-79. 7%) . The median overall survival was 17 months (95% CI: 14-20 months) . Patients with PD-L1 tumor proportion scores (TPS) ≥ 50% had a higher median OS of 24 months compared to 14 months in PD-L1-negative cases. Adverse events were reported in 40% of patients, with 9. 3% experiencing grade 3 or 4 toxicities, including pneumonitis (3%), diarrhea (2%), and transaminitis (1 . 5%) .  \n*Correspondence:  \nOumaima Siyouri [Oumaima.siyouri.os@gmail.com](Oumaima.siyouri.os@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nBenbrahim et al. BMC Cancer (2026) 26:267 Page 2 of 6  \nConclusion These results highlight the efficacy of immu","cbCaicNL6OwqkJ8D","https://ap.wps.com/l/cbCaicNL6OwqkJ8D","pdf",1044418,"English","# Abstract\n## Introduction\n## Methods\n## Results\n## Conclusion","[{\"question\":\"What was the main objective of the study on immune checkpoint inhibitors in lung cancer?\",\"answer\":\"To evaluate how immune checkpoint inhibitors were used for lung cancer and to assess the real-world data from Morocco.\"},{\"question\":\"What study design and patient time window were used?\",\"answer\":\"A retrospective, multicenter cohort study included Moroccan patients diagnosed between January 2019 and January 2022 and treated with ICIs.\"},{\"question\":\"What survival outcomes and safety signals were reported?\",\"answer\":\"The median time to discontinuation was 13.53 months, with 12-month overall survival of 71.1% and median overall survival of 17 months; adverse events occurred in 40%, with grade 3–4 toxicities in 9.3%.\"}]","Brief report: immune checkpoint inhibitors use in lung cancer - a real-world outcome study in a middle-income country | PDF",1790147836,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa86eaf2b2cb6e66362b4c568c7cac1b.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c2ec40f9122674b885d95fadb3b0e00.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99dab38f122248e85873e19265a79a35.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/625468c2f78aea45fd84967e22b854ae.webp",980,1306]